A Meta-Analysis of Efficacy and Safety of PD-1/PD-L1 Inhibitors in Triple-Negative Breast Cancer

Figure 3

Forest plots of anti-PD-1/PD-L1 in overall TNBC. (a) PFS. (b) OS. SE: standard error; CI: confidence interval; TNBC: triple-negative breast cancer; PD: progression death; OS: overall survival; PFS: progression-free survival.

(a)

(b)